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Summary
Although today among oncology patients use of various preparations of complementary and alternative medicine is 
more and more frequent, there is unequivocal scientifi c base for their use. Among the often used preparations, especially in 
the treatment of cancer pain, is cannabis and its derivatives. Cannabinoids act on the endogenous cannabinoid system, with 
widespread receptors in the central nervous system and peripheral tissues. Although the pharmacology of the cannabinoids 
is still largely unknown, numerous of their eff ects were investigated. In oncology, studies have been conducted on the eff ect 
of cannabinoids on nausea and vomiting during the oncological treatment, the cancer pain and neuropathy, on appetite and 
weight loss, and the impact on mood, depression and anxiety. It is also observed that some of the cannabinoids have antitu-
mor, but also protumorous activity. There have been many diff erent side eff ects of cannabinoids detected, and in a smaller 
percentage also the development of addiction. Best known preparations nowadays are dronabinol, nabilon and nabiximol. 
At the moment, the evidence lack strenght, and large randomized clinical trials are required, which would confi rm pre-
dominatly positive results of the research.
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MEDICINSKA KONOPLJA U ONKOLOGIJI
Sažetak
Iako je danas među onkološkim bolesnicima sve učestalija uporaba različitih pripravaka komplementarne i alternativne 
medicine, za njihovu uporabu nema nedvojbene znanstvene potvrde. Među češće primjenjivanim pripravcima, osobito u 
 liječenju karcinomske boli, je i kanabis i njegovi derivati. Kanabinoidi djeluju u organizmu preko endokanabinoidnog susta-
va, s rasprostranjenim receptorima u središnjem živčanom sustavu i perifernim tkivima. Iako je farmakologija kanabinoida 
još uvijek uglavnom nepoznata, do sada su istraživani njihovi brojni učinci. U onkologiji su provedena istraživanja utjecaja 
na mučninu i povraćanje prilikom onkološkog liječenja, na karcinomsku bol te neuropatiju, na apetit i gubitak tjelesne mase 
te utjecaj na raspoloženje, depresiju i tjeskobu. Također je opažen antitumorski, ali i protumorski učinak nekih kanabinoida. 
Zabilježeni su brojni različiti neželjeni učinci kanabinoida, a u manjem postotku i razvoj ovisnosti. Najpoznatiji pripravci 
danas jesu dronabinol, nabilon i nabiksimol. Sveukupno, za sada nisu osigurani dovoljno snažni i nedvojbeni dokazi i potreb-
ne su velike randomizirane kliničke studije, koje bi potvrdile do sada opažene pozitivne rezultate istraživanja.
KLJUČNE RIJEČI:  CAM, kanabis, medicinska konoplja, kanabinoidi, CB1, CB2, karcinomska bol, kaheksija, kemoterapijom 






Use of complementary and alternative medi-
cine (CAM) is nowadays all the more frequent 
among cancer patients. Research results speak for 
variable range of application, 7-64% (1). Even-
though the use increases, there is no satisfactory 
evidence in studies on the eff ectiveness of CAM. 
Level of evidence for diff erent types of interven-
tions (acupuncture, refl exology, massage, TENS, 
psychosocial support, education, Chinese herbal 
medicine, music therapy, homeopathy) is small to 
moderate. In the reduction of malignant pain in 
cancer patients acupuncture in combination with 
drugs, Chinese herbal medicine, homeopathy, re-
fl exology and cannabis have proven to have some 
eff ect (2). Studies on CAM are diffi  cult to compare, 
because the samples are very diff erent, there are 
many methodological weaknesses and a high 
probability of systematic errors, and there are 
many nonstandardized methods of application of 
CAM (3). According to the study from 2014, on 27 
systematic reviews, it is not advisable to apply the 
CAM in any way in the treatment of adult patients 
with malignant disease who suff er pain (2).
Cannabinoids
Cannabinoids are the active components of 
the plant Cannabis sativa, and there are about 60 
of them known so far. Pharmacology of cannabi-
noids is mostly unknown. The two best known 
derivatives are tetrahydrocannabinol (THC) and 
cannabidiol (CBD), as weak derivative and deriva-
tive without any cannabimimetic activity. Canna-
binoids act on the endogenous cannabinoid sys-
tem and its role in brain neuromodulation via two 
types of receptors, CB1 and CB2 (4). CB1 receptors 
are associated with central and peripheral eff ects. 
They are permanently expressed in the part of the 
brain responsible for motor activity, memory and 
understanding, emotions, sensory and autonomic 
functions and endocrine function, as well as in pe-
ripheral nerve endings, but also in diff erent extra-
neural parts, such as the testes, eyes, spleen, etc., 
CB2 receptors are exclusively present in the im-
mune system, associated with the cells (T and B 
lymphocytes, macrophages) or with organs (liver, 
tonsils, lymph nodes) (5). Beside endocannabi-
noids, there are three basic structural groups of 
cannabinoid agonists/ ligands, such as classical 
cannabinoid THC analogs, nonclassical bicyclic 
and tricyclic cannabinoid analogues of THC and 
aminoalkylindols. All of them served for thorough 
pharmacological research and as design models 
for clinically useful substances (6).
Cannabis - panacea or psychoactive drug?
Cannabis’ use in medicine began in the 19th 
century, when it was recognized as analgesic, sed-
ative, anti-infl ammatory, antispasmodic and anti-
convulsant agent. In the 20th century cannabis has 
been removed from the US pharmacopoeia and in 
the 1970’s marijuana was listed as group I sub-
stance, substance with a high potential for abuse, 
along with drugs such as LSD, heroin, mescaline, 
etc. (7). According to some opinion, cannabis is 
like medicine for all, yet, according to many, dan-
gerous illegal drug with psychogenic eff ects. It is 
known that cigarett e smoke is carcinogenic, and 
that THC has psychoactive eff ects. Today, some 
cannabis derivatives are approved as prescription 
drugs, while the plant itself (hemp, other than in-
dustrial) remains to be a prohibited drug.
Out of drugs based on cannabis, nabiximol is 
the only natural extract of the whole plant, in 
spray formulation, and is commonly used in pa-
tients with multiple sclerosis. It was tested also as 
a pain releasing therapy among cancer patients 
(8). Most studies have investigated dronabinol, 
which according to the composition equals syn-
thetic THC. The third most frequently used com-
position is nabilone, also synthetic analog of THC, 
which is investigated, same as dronabinol, as an 
antiemetic agent. Cannabis-based preparations 
may be in the form of oils, sprays, capsules or in 
the form of cigarett es.
Anti-tumor eff ect
Numerous studies in animal models and cell 
lines have shown that there is a potential for anti-
tumor eff ect of cannabis and there was a kind of 
anti-tumor eff ect detected, which is not unequivo-
cally proven at this time. However, it is found that 
cannabis interferes in key cell signaling pathways 
and thus can directly induce cessation of cell 
growth and cell death. Also, it has been shown to 
prevent tumor angiogenesis and metastasis (9). 
The question of infl uence on normal cells is also 
not completely elucidated, but it is possible that 
53
Lib Oncol. 2016;44(2–3):51–57
it’s all about diff erent pathways and regulatory 
mechanisms of cell survival and death in tumor 
and non-tumor cells (10).
According to the research conducted so far it 
has been shown that cannabis aff ects invasion and 
cell proliferation in human breast cancer (11), due 
to the large number of CB receptors it may repre-
sent a potential therapeutic target to slow the 
growth of tumor cells in lung cancer (12), and a 
Spanish pilot clinical study applied the THC intra-
cranially, through an infusion catheter and in pa-
tients with recurrent glioblastoma it showed slow-
ing growth in 2/9 of patients undergoing treat-
ment (13). However, despite the large number of 
pre-clinical studies, as well as sporadic individual 
examples, in which a certain eff ect was detected, 
there is no suffi  cient evidence in the clinic. There-
fore, there is no hard evidence for counseling pa-
tients to stop the standard treatment and use high-
ly potent extracts of cannabis. The arguments in 
favor of this are based on the testimonies of pa-
tients with skin cancer, which topically applied oil 
composition of cannabis on the skin.
Cannabis in oncology
Cannabis has been studied in cancer patients 
as possible antiemetic therapy, to improve appetite, 
as an analgesic, to relieve neuropathy and in anxi-
ety, depression and for the improvement of sleep.
Antiemetic eff ect
The studies of antiemetic eff ect were usually 
conducted with dronabinol. Based on the results 
of these studies, dronabinol is as an antiemetic ap-
proved in the United States. A systematic review 
of 30 randomized trials comparing cannabis to 
placebo and the standard antiemetic therapy from 
2001, over 1360 patients showed signifi cantly 
greater antiemetic eff ect of cannabinoids nabilone 
and dronabinol, compared to the control group 
(14). A similar conclusion was conducted in a 
small study in 2010, that gave rise to nabiximol 
(15). Analysis of the 15 controlled studies that 
have compared the antiemetic eff ect of nabilone to 
placebo and standard antiemetic, in over 600 pa-
tients showed a greater eff ect of nabilone, and it 
was even preferred by patients (16). Analysis of 
studies investigating smoking cannabis proved 
positive antiemetic eff ect, but patients mostly pre-
ferred oral preparation. The results of these stud-
ies were sometimes contradictory, but if a positive 
eff ect was determined, it should have been consid-
ered as a substitute for dronabinol, if the patients 
can not tolerate it (7). A small study in 2007, com-
paring cannabis to newer antiemetics, such as on-
dansetron, showed similar effi  cacy and the lack of 
additive eff ect of the combination of these prod-
ucts (17). That gave a hint about potential econom-
ic benefi t of cannabis in this indication, but also 
the need for further research and larger studies 
comparing cannabis and these preparations.
Eff ect on appetite and weight loss
Among studies of the impact of cannabis on 
appetite there are very few adequate ones, and 
they also most frequently tested the eff ect of 
dronabinol. In two small studies, conducted in the 
past decade, it has been shown that oral THC 
stimulates appetite and that it can slow down the 
loss of appetite in advanced cancer. One large ran-
domized double-blind study in almost 470 cancer 
patients with advanced cancer and loss of body 
weight (BW) compared the daily administration 
of THC to a standard agent in this indication, 
megestrol acetate, and both preparations together, 
and it appears that signifi cantly bett er results were 
seen in the group of the megestrol acetate, and a 
combination therapy showed no additional eff ect, 
the two compositions are not therefore to have 
any additive eff ects (7). It appears that the endog-
enous cannabinoid system is actually responsible 
for the regulation of eating habits (18).
Analgesic eff ect
In the studies of the analgesic eff ect of can-
nabis it has been proven that a possible way of en-
dogenous cannabinoid system activity in pain 
modulation works through the anti-infl ammatory 
mechanism via CB2 receptors, by releasing of anti-
infl ammatory substances and increased release of 
the opioid analgesics (19). Central action of can-
nabinoids is diff erent from opioid, it is not blocked 
by opioid antagonists. This positions marijuana as 
a potential adjunctive therapy with opioids. Early 
studies on the impact of cannabinoids on (experi-
mental) pain in healthy volunteers have been in-
conclusive. Some have shown no eff ect, some have 
even shown hiperalgesic eff ect, and analysis de-
termined the existence of a number of method-
ological errors in the performance of the research 
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(20). The three pivotal studies of the eff ect of THC 
on cancer pain, from the mid-1970’s, have shown 
that THC effi  ciency is comparable to that of co-
deine (21, 22, 23). In the study on eff ect of adding 
THC to chronic opioid therapy it has been shown 
that the best eff ect on pain relief was in a group on 
a proportionate amount of THC and CBD (24).
Eff ect on neuropathy
Patients receiving chemotherapy with vinca 
alkaloids, taxanes or platinum compounds often 
present with painful sensory peripheral neuropa-
thy. In studies with smoking cannabis it has been 
shown that it has twice the eff ect on the reduction 
of neuropathic pain (52% vs. 24%, 30% reduction 
of pain) compared to placebo, and the eff ect is spe-
cially expressed in the fi rst cigarett e of cannabis 
(eff ect up to 70%) (25). The two studies on the im-
pact of cannabinoids on central neuropathic pain 
in patients with multiple sclerosis have shown 
that THC sublingual spray, alone or in combina-
tion with the CBD has a double eff ect on pain re-
duction, in comparison to placebo. CBD mono-
therapy showed no eff ect (26). Chronic adminis-
tration of the CBD in animal models prevented the 
occurrence of chemotherapy-induced neurotoxic-
ity (27). Despite the promising results, in order to 
prove unambiguous clinically signifi cant eff ect of 
cannabinoids on neuropathy, further large pro-
spective randomized clinical studies are needed.
Eff ect on mood changes
In studies with cannabis often as a side eff ect 
occurs euphoria, which among other things de-
pends on the patient’s previous experience with 
cannabis. In some patients dysphoria with or with-
out paranoia is recorded, and in these patients, can-
nabis and cannabis derivatives remain without 
clinical eff ect. In studies of nabiximol and inhaled 
cannabis the improvement of the quality of sleep 
and falling asleep is detected (28, 29). Analyses of-
ten concluded that cannabis is useful to consider in 
patients with cancer and anorexia, nausea, pain, 
depression, anxiety and insomnia, because it estab-
lished eff ect on all of these problems.
Indications for cannabis in oncology
Indications for cannabis in oncology today 
are nausea and vomiting, cachexia and stimulat-
ing appetite, pain and psychological impact.
According to guidelines cannabinoids are a 
potential third or fourth line antiemetic therapy, 
when standard treatments are not eff ective (30). 
According to present knowledge, in this situation 
an independent application of dronabinol can be 
considered. The optimal dose of dronabinol is 5 
mg / m² per day, to a maximum of six doses. The 
application of dronabinol starts before chemother-
apy and then continues through several postt hera-
peutic days. If ineff ective, the dose may be in-
creased during application of chemotherapy (31). 
Today approved drugs for this indication are 
dronabinol and nabilone. They have been shown 
to be eff ective in delayed emesis, after fi rst 24 
hours after chemotherapy administration, in the 
phase in which the emesis is usually poorly con-
trolled (32). As mentioned above, it is necessary 
once more, thoroughly, through large prospective 
randomized studies to compare in this indication 
the eff ect among diff erent cannabinoids and can-
nabinoids and todays’ modern antiemetics, such 
as setrons and NK antagonists.
The problem of the appetite loss and loss of 
the body weight is present in over 50% of cancer 
patients. There are ongoing phase II studies, that 
aim to determine the relationship between in-
creased appetite and prevention of body weight 
loss, after treatment with THC in cancer patients. 
The recent phase III study demonstrated the eff ect 
of THC in improving appetite in cancer patients 
with advanced disease, and it is administered at a 
dose of 5 mg daily (33). Dronabinol is indicated 
for the treatment of anorexia in patients suff ering 
from AIDS, in a dosage of 2.5 - 5 mg per day (34). 
Future large studies have the role of proving a 
defi nite eff ect of cannabinoids in the treatment of 
anorexia and cachexia, through the comparison 
with the standard (megestrol acetate), which has 
not yet yielded unambiguous results.
As noted, the analgesic eff ect of cannabis and 
cannabinoids (dronabinol, nabiximol, nabilone, 
natural THC itself, CBD, smoked marijuana) was 
recorded in a number of studies with diff erent de-
signs and quality, especially in studies with ani-
mal models. A meta-analysis of studies of analge-
sia in humans is not applicable, because studies 
conducted so far are not comparable, due to dif-
ferences in methodology, sampling, the method of 
application preparations etc. It is clear that chronic 
cancer pain consists of more components, thus 
pharmacological approach should include action 
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on peripheral nerves, as well as on the spinal cord 
and brain. The only product that has regulatory 
approval in some countries for use as pain releas-
ing therapy in malignancies, and that in case of 
ineffi  ciency of the strong opioids, as adjunct ther-
apy, is nabiximol. It is used as a spray, at a dose of 
12 activations daily (35). There are ongoing stud-
ies on antidolorous eff ect of cannabinoids in the 
terminal stage malignancies.
According to studies on animal models can-
nabinoids reduce anxiety (36). Only a few studies 
that have examined the eff ect of cannabinoids on 
the mood in cancer patients have indicated a posi-
tive eff ect, with many restrictions. THC and nabi-
lone may lead to positive psychological eff ects, 
reduction of depression and anxiety and sleep im-
provement (37).
Adverse eff ects
Among the harmful eff ects of cannabis aff ec-
tive, sensory, somatic and cognitive type of ad-
verse eff ects can be seen (38). Since the receptors 
for cannabinoids are ubiquitous in human organ-
ism, use of cannabinoids can cause symptoms in 
multiple organ systems: cardiovasculary, respira-
tory, gastrointestinal and musculoskeletal. Fortu-
nately, symptoms are generally rare, mild and dis-
sappear spontaneously. Chronic smokers may ex-
perience withdrawal syndrome, and there is also 
fatigue, insomnia, irritability and hot fl ashes (39). 
Tolerance on cannabinoids develops quickly. This 
is mainly due to pharmacodynamic changes, re-
ducing the total and number of functional recep-
tors on the cell. Less it is due to pharmacokinetic 
changes (biotransformation and excretion) (40). 
Central and peripheral eff ects of cannabinoids are 
diff erent, sometimes amplifi ed in recreational use 
of cannabis (41). The risk of addiction by pro-
longed use of cannabis is 9%, lower than for hero-
in or other opiates (42).
(Pro)tumorous eff ect
Research of (pro)tumorous eff ect of cannabis 
has not have off ered unmistakable conclusion. 
Studies of associations between smoking marijua-
na and cancer are mostly studies of pairs (smok-
ing / non-smoking). Those research are unreliable 
because of limitations in the studies’ design. 
Smoking proved to be a confounding factor (43). 
One study showed a connection between marijua-
na with cancer of the head and neck (44), while 
others have not observed positive correlation. In-
creased risk is neither unambiguously established 
in the lung cancer: one Swedish study showed 
long-term increased risk, but patients were tobac-
co smokers in the same time (45). Among other 
types of cancer, two studies have shown an in-
creased risk of testicular cancer, increased risk of 
developing cancer of the urinary bladder (46, 47), 
but in these studies a confounding factor was also 
smoking tobacco in many subjects.
Cannabis today
As a result of the new regulatory rules today 
a number of products based on cannabinoids, as 
well as numerous ways of their use become more 
and more accessible. This is especially important 
for patients and their families, but also in the sci-
entifi c community, especially after a long pause in 
studying of cannabis. The problem today is the 
fact that many health care workers do not have the 
basic knowledge on cannabis, cannabinoids, nei-
ther of the endocannabinoid system. In this way, 
an adequate fl ow of information from the doctor 
to the patient is disabled. This prevents the patient 
to reach valuable tips and thereby weakens the 
quality of relations between doctors and patients. 
It is the duty and obligation of all medical profes-
sionals to critically monitor and use information 
in this area.
It is clear that the development and accep-
tance of cannabis preparations in other formula-
tions (except smoking) is very likely a longlasting 
process. However, at the same time a lot of pa-
tients can benefi t greatly in disposing side eff ects 
of chemotherapy and malignancy itself (nausea, 
vomiting, decreased appetite, cachexia pain, anxi-
ety, depression, insomnia), but there are also anti-
cancer properties.
Health workers are more likely to prescribe 
much more expensive and certainly more harmful 
pharmaceutical preparations, leaving cannabis 
aside. However, it is recommended to assess the 
indication and use the cannabis in practice as any 
other medical product. It takes a structured ap-
proach to the patient and treatment plan, a well-
kept medical records, and clearly evident reason 
for the application. As there is no clear universal 
recommendation on the application, it is neces-
sary to build na individual paradigm of applica-




 1. Adams M, Jewell P A; The Use of Complementary and 
alternative Medicine by cancer patients, International 
Seminars in Surgical Oncology, vol 4, article 10, 2007.
 2. Bao Y, Kong X, Yang L, Liu R, Shi Z, Li W et al; Com-
plementary and Alternative Medicine for Cancer Pain: 
an Overview of Systematic Reviews, Hindawi Pub-
lishing Corporation, Evidence-Based Complementary 
and Alternative Medicine, Vol 2014, Article ID 170396.
 3. Running A, Seright T; Integrative Oncology: managng 
cancer pain with complementary and alternative ther-
apies, Current Pain and Headache Reports, vol. 16, no. 
4, pp. 325 – 331, 2012.
 4. Guzman M; Cannabinoids: potential anticancer agents, 
Nature Reviews. Cancer, Vol 3, Oct 2003.
 5. Howlett  A C et al; International Union of Pharmacol-
ogy. XXVII. Classifi cation of cannabinoid receptors. 
Pharmacol Rev. 54, 161 – 202 (2002).
 6. Pertwee R G; Cannabinoid receptor ligands: clinical 
and neuropharmacological considerations, relevant to 
future drug discoveryand development. Expert Opin. 
Investig. Drugs. 9, 1553 – 1571 (2000).
 7. Abrams D I, Guzman M; Cannabis in cancer care. Ac-
cepted Article, doi: 10.1002/cpt.108
 8. Portenoy R K, Banae –Motan E D, Allende S et al; 
Nabiximol for opioid – treated cancer patients with 
poorly – controlled chronic pain: a randomized pla-
cebo- controlled dose-graded trial. J Pain 2012; 13: 
438 – 449.
 9. Guzman M; Cannabinoids: potential anticancer agents. 
Nature Reviews/Cancer 2003; 3: 745 – 755.
10. Bifulco M, Laezza C, Pisanti S, Gazzerro P; Canna-
binoids and cancer: pros and cons of an antitumor 
strategy. British Journal of Pharmacology 2006; 148: 
123 – 135.
11. De Petrocellis L, Melck D, Palmisano A, Bisogno T, 
Laezza C, Bifulco M, et al; The endogenous cannabi-
noid anandamide inhibits human breast cancer cell 
proliferation. Proc Natl Acad Sci 1998; 95: 8375 – 8380.
12. Preet A, Ganju R K, Groopman J E; Δ9-Tetrahy-
drocannabinol inhibits epithelial growth factor-in-
duced lung cancer cell migration in vitro as well as its 
growth and metastasis in vivo. Oncogene (2008) 27, 
339–346.
13. Guzman M, Duarte M J, Blazquez C, Ravina J, Rosa M 
C, Galve – Roperh I et al; A pilot sudy of delta – 9 – 
tetrahydrocannabinol in patients with recurrent glio-
blastoma multiforme. British Journal of Cancer. 2006, 
1-7.
14. Tramer M R, Carroll D, Campbell F A, Reynolds D J, et 
al; Cannabinoids for control of chemotherapy induced 
nausea and vomiting: quantitative systematic review. 
BMJ 2001; 323: 16 – 21.
15. Duran M, Perez E, Abanades S, Vidal X et al; Preli-
minary effi  cacy and safety of an oromucosal stan-
dardized cannabis extract in chemotherapy – induced 
nausea and vomiting. BR J Clin Pharmacol 2010; 70: 
656 – 663.
16. Ben Amar M; Cannabinoids in medicine: a review of 
their therapeutic potential. J Ethnopharmacol 2006; 
105: 1 – 25.
17. Meiri E, Jhangiani H, Vredenburgh J J, Barbato L M, et 
al; Effi  ciacy of dronabinol alone and in combination 
with ondansetron versus ondansetron alone for de-
layed chemotherapy induced nausea and vomiting. 
Curr Med Res Opin 2007; 3:533 – 543.
18. Mechoulam R, Berry E M, Avraham Y, DiMarzo V, 
Fride E; Endocannabinoids, feeding and suckling – 
from our perspective. Int J Obes (Lond.) 2006; Suppl 1: 
S24 – S28.
19. Ibrahim M M, Porreca F, Lai J, albrecht P J, Rice F L, 
Khodorova A et al; CB2 cannabinoid receptor activa-
tion produces antinociception by stimulating periph-
eral release of endogenous opioids. Proc Natl Acad 
Sci. 2005;102: 3093–3098.
20. Joy J E, Watson S J, Benson J A; Marijuana and medi-
cine: assessing the Science Base. Washington DC; Na-
tional Academy Press, 1999.
21. Noyes R, Brunk S, Baram D, Canter A; Analgesic Ef-
fect of delta – 9 – tetrahydrocannabinol. Journal of 
Clinical Pharmacology 1975;15:139–143.
22. Noyes R, Brunk S, Avery D, Canter A; The analgesic 
properties of delta – 9 – tetrahydrocannabinol and co-
deine. Clinical Pharmacology and Therapeutics 1975; 
18:84–89.
23. Noyes R, Baram D; Cannabis analgesia. Compr Psy-
chiatry 1974;15:531.
24. Johnson J R, Burnell – Nugent M, Lossignol D et al; 
Multicenter double – blind, randomized, placebo – 
controlled, parallel – group study of the effi  ciacy, safe-
ty and tolerability of THC:CBD extract and THC ex-
tract in patients with intractable cancer – related pain. 
Journal of Pain and Symptom Management 2010;39
(2):167–178.
25. Abrams D I, Jay C, Shade S, Vizoso H, Reda H, Press S, 
et al; Cannabis in painful HIV – associated sensory 
neuropathy: a randomized, placebo – controlled trial. 
Neurology 2007;68:515–521.
26. Rog D J, Nurmikko T J, Fride T, Young C A; Random-
ized, controlled trial of cannabis – based medicine in 
central pain in multiple sclerosis. Neurology. 2005; 
65:812–819.
27. Ward S J, McAllister S D, Neelakantan H, Walker E A; 
Cannabidiol inhibits paclitaxel – induced neuropathic 
pain through 5 – HT1A receptors without diminishing 
nervous system function or chemotherapy effi  ciacy. 
Br J Pharmacol 2014;171:636– 45.
28. Russo E B, Guy G W, Robson P J; Cannabis, pain and 
sleep: lessons from therapeutic clinical trials of Sa-
tivex®, a cannabis – based medicine. Chemistry & Bio-
diversity 2007;4:1729–1743.
29. Ware M A, Wang T, Shapiro S et al; Smoked cannabis 
for chronic neuropathic pain: A randomized con-
trolled trial. CMAJ 2010;182(14):E694–701.
57
Lib Oncol. 2016;44(2–3):51–57
30. Walsh D, Nelson K A, Mahmoud F; Established and 
potential therapeutic applications of cannabinoids 
in oncology. Supportive Care in Cancer 2003; 11(3): 
137–143.
31. Braff ord M M, Glode A E; Dronabinol for chemothera-
py-induced nausea and vomiting unresponsive to an-
tiemetics. Cancer Manag Res. 2016;8:49–55.
32. Slatkin N E; Cannabinoids in the Treatment of Che-
motherapy-Induced Nausea and Vomiting: Beyond 
Prevention of Acute Emesis. J Support Oncol 2007;5
(suppl 3):1–9.
33. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller 
T, Meissner W, et al; Comparison of Orally Adminis-
tered Cannabis Extract and Delta-9-Tetrahydrocan-
nabinol in Treating Patients With Cancer-Related An-
orexia-Cachexia Syndrome: A Multicenter, Phase III, 
Randomized, Double-Blind, Placebo-Controlled Clini-
cal Trial From the Cannabis-In Cachexia-Study-
Group. Journal of Clin Oncol. 2006;24(21):3394-3400.
34. Beal J E, Olson R, Laubenstein L, Morales J O, Bellman 
P, Yangco B, et al; Dronabinol as a treatment for an-
orexia associated with weight loss in patients with 
AIDS. Journal of Pain and Symptom Management. 
1995;10:89-97.
35. Johnson J R, Lossignol D, Burnell-Nugent M, Fallon M 
T; An open-label extension study to investigate the 
long-term safety and tolerability of THC/CBD oromu-
cosal spray and oromucosal THC spray in patients 
with terminal cancer-related pain refractory to strong 
opioid analgesics. J Pain Symptom Manage. 2013;46
(2):207-18.
36. Panlilio L.V, Justinova Z, Goldberg S. R; Animal mod-
els of cannabinoid reward. Br J Pharmacol. 2010;160
(3):499–510.
37. Robson P; Therapeutic aspects of cannabis and can-
nabinoids. The British Journal of Psychiatry 2001;178
(2):107-115.
38. Degenhardt L, Hall W D; The adverse eff ects of can-
nabinoids: implications for use of medical marijuana. 
CMAJ. 2008;178(13):1685–1686.
39. Jones RT, Benowitz  NL, Herning RI; Clinical relevance 
of cannabis tolerance and dependence. J Clin Pharma-
col. 1981;21(Suppl 8–9):143S–52.
40. Grotenhermen F; Pharmacokinetics and Pharmacody-
namics of Cannabinoids. Clinical Pharmacokinetics. 
2003;42(4):327–360.
41. Martín-García E, Burokas A, Martín M, Berrendero F, 
Rubí B, Kiesselbach C, et al; Central and peripheral 
consequences of the chronic blockade of CB1 cannabi-
noid receptor with rimonabant or taranabant. J Neuro-
chem. 2010;112(5): 1338-13351.
42. Volkow N D, Baler R D, Compton W M, Weiss S R B; 
Adverse health eff ects of marijuana use. N Engl J Med 
2014;370:2219–2227.
43. Huang YH, Zhang ZF, Tashkin DP, FengB, Straif K, 
Hashibe M. An epidemiologic review of marijuana 
and cancer: an update. Cancer Epidemiol Biomarkers 
Prev. 2015;24(1):15-31.
44. Aldington S, Harwood M, Cox B, Weatherall M, Beck-
ert L, Hansell A, et al; Cannabis use and cancer of the 
head and neck: Case-control study. Otolaryngol Head 
Neck Surg. 2008;138(3):374–380.
45. Callaghan R C, Allebeck P, Sidorchuk A; Cannabis use 
and risk of lung cancer: a 40 – year cohort study of 
Swedish men; European Journal of Public Health, 
2014; 24(Suppl.2):126.
46. Trabert B, Sigurdson A J, Sweeney A M, et al; Mari-
juana use and testicular germ cell tumors. Cancer 
2011;117(4):848–853.
47. Thomas A A, Wallner L P, Quinn V P, Slezak J, Van 
Den Eeden S K, Chien G W, et al; Association between 
cannabis use and the risk of bladder cancer: results 
from the California Men’s Health Study.Urology. 2015 
Feb;85(2):388-92.
Corresponding author: Robert Šeparović, Deparment of 
Medical Oncology, University Hospital for Tumors, Uni-
versity Hospital Center Sestre milosrdnice, Ilica 197, 
10000 Zagreb, Croatia. e-mail: rseparov@gmail.com
